Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia.
chronic lymphocytic leukemia
disseminated intravascular coagulopathy
obinutuzumab
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
pubmed:
20
1
2021
medline:
18
8
2021
entrez:
19
1
2021
Statut:
ppublish
Résumé
Infusion-related reactions are among the worst complications of obinutuzumab (G) administration and occur predominantly during the first infusion. We reported another adverse event related to the first G infusion, a subclinical coagulopathy. We retrospectively analyzed a cohort of 13 pts with chronic lymphocytic leukemia treated with a frontline G-chlorambucil regimen. Six pts developed non-overt disseminated intravascular coagulopathy (DIC) (46%) after the first administration of G. The coagulopathy was subclinical and self-limited in all pts, not requiring any intervention apart from the suspension of anticoagulant therapy in one pt. We observed a drop in the platelet count, an elevation of D-dimer levels, and an elongation of activated partial thromboplastin time. We found a significant difference in the platelet count between the pts with DIC and those withouts; in fact, all the six pts with non-overt DIC had a platelet count greater than 100 × 10
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Chlorambucil
18D0SL7309
obinutuzumab
O43472U9X8
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
423-427Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Therapeut. 2013;12(10):2031-2042. https://doi.org/10.1158/1535-7163.MCT-12-1182.
Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011;117(17):4519-4529. https://doi.org/10.1182/blood-2010-07-296913.
Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-1110. https://doi.org/10.1056/NEJMoa1313984.
Goede V, Fischer K, Dyer MJS, et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. EHA Library. 215923; S151 Topic: 3Aj Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Herishanu Y, Shaulov A, Fineman R, et al. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. Am J Hematol. 2020;95(6):604-611. https://doi.org/10.1002/ajh.25766.
Walter HS, Jayne S, Mensah P, Miall FM, Lyttelton M, Dyer MJ. Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12. Blood Cancer J. 2016;6(6):e435. https://doi.org/10.1038/bcj.2016.42.
Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760. https://doi.org/10.1182/blood-2017-09-806398.
Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc. 1995;43(2):130-137. https://doi.org/10.1111/j.1532-5415.1995.tb06377.x.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. https://doi.org/10.1159/000180580.
Wada H, Hatada T, Okamoto K, et al. Modified non-overt DIC diagnostic criteria predict the early phase of overt-DIC. Am J Hematol. 2010;85(9):691-694. https://doi.org/10.1002/ajh.21783.
Moresco RN, Vargas LC, Voegeli CF, Santos RC. D-dimer and its relationship to fibrinogen/fibrin degradation products (FDPs) in disorders associated with activation of coagulation or fibrinolytic systems. J Clin Lab Anal. 2003;17(3):77-79. https://doi.org/10.1002/jcla.10072.
Moresco RN, Júnior RH, Cláudio Rosa Vargas L, Mariano da Rocha Silla L. Association between plasma levels of D-dimer and fibrinogen/fibrin degradation products (FDP) for exclusion of thromboembolic disorders. J Thromb Thrombolysis. 2006;21(2):199-202. https://doi.org/10.1007/s11239-006-4837-9.
Cheson BD, Heitner Enschede S, Cerri E, et al. Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents. Oncologist. 2017;22(11):1283-1291. https://doi.org/10.1634/theoncologist.2017-0055.
Liaw PC, Ito T, Iba T, Thachil J, Zeerleder S. DAMP and DIC: the role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. Blood Rev. 2016;30(4):257-261. https://doi.org/10.1016/j.blre.2015.12.004.
Freeman CL, Morschhauser F, Sehn L, et al. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood. 2015;126(24):2646-2649. https://doi.org/10.1182/blood-2015-09-670802.
Freeman CL, Dixon M, Houghton R, et al. Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia. 2016;30(8):1763-1766. https://doi.org/10.1038/leu.2016.41.
Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016;2:16037. https://doi.org/10.1038/nrdp.2016.37.